Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

SureCN1649552 2-[[2-[[3- (diaminomethylidene)-6-oxo- 1...

Synonyms: FT-0668536, AC1O5FK6

Post, J.M. et al., Abendschein, D.R. et al., Adler, M. et al., Phillips, G.B. et al., Abendschein, D.R. et al., et al.

Chi, Pen, Potoczak, Gibson, Hicks, Mertz, Janiczek, Juneau, Gallagher, Leadley, Post, Sullivan, Abendschein, Ewing, Hinchman, Light, Abendschein, Baum, Verhallen, Eisenberg, Sullivan, Light, McLean, Schirm, Johns, Morser, Light, McClanahan, Hicks, Morrison, Peng, Janiczek-Dolphin, Mertz, Sullivan, Morser, Juneau, Leadley, Abendschein, Baum, Martin, Vergona, Post, Rumennik, Sullivan, Eisenberg, Light,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ZK 807834

The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis [1].
Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor [2].
These cellular responses, which may complicate vascular disease, are inhibited by ZK-807834 [3].

High impact information on ZK 807834

The crystal structure of the complex shows that the amidine of ZK-807834 forms a salt bridge with Asp189 in the S1 pocket and the basic imidazoline fits snugly into the S4 site [4].
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa [5].
This study was designed to determine whether a novel, synthetic inhibitor of FXa (ZK-807834, molecular mass 527 Da, K(i) = 0.11 nM) administered during and briefly after pharmacologic coronary fibrinolysis increases 24-h patency [6].
Studies in animals have shown that ZK-807834 attenuates thrombosis and thrombus progression after fibrinolysis and exhibits an increased antithrombotic-to-bleeding risk ratio compared with conventional agents [7].
Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031) [7].

Biological context of ZK 807834

Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were unchanged from baseline at the minimally effective dose of ZK-807834, whereas aPTT was increased twofold at the effective dose of LMWH [8].
ZK-807834 exhibited no direct effect on ADP- or collagen-induced platelet aggregation [7].
Thus ZK-807834 may be useful to attenuate thrombosis at lower dosages and with less perturbation of systemic hemostasis compared with available agents [8].
Consistent with its selective inhibition of Factor Xa, ZK-807834 in the range of 0.3-0.5 microM prolonged prothrombin time (PT) and activated partial thromboplastin time (aPPT) twofold without affecting thrombin time (TT) [7].

Gene context of ZK 807834

ZK-807834 also was compared with low molecular weight heparin (LMWH; MW, 5,500 D) during venous thrombosis induced by placing a copper wire and threads in the vena cava [8].

Analytical, diagnostic and therapeutic context of ZK 807834

This paper presents the structure of the inhibitor ZK-807834, also known as CI-1031, bound to factor Xa and provides the details of the protein purification and crystallization [4].

References

The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. McClanahan, T.B., Hicks, G.W., Morrison, A.L., Peng, Y.W., Janiczek-Dolphin, N., Mertz, T.E., Sullivan, M.E., Morser, J., Juneau, P.L., Leadley, R. Eur. J. Pharmacol. (2001) [Pubmed]
Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor. Chi, L., Pen, Y.W., Potoczak, R., Gibson, G., Hicks, G., Mertz, T.E., Janiczek, N., Juneau, P.L., Gallagher, K., Leadley, R. Pharmacology (2002) [Pubmed]
FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. McLean, K., Schirm, S., Johns, A., Morser, J., Light, D.R. Thromb. Res. (2001) [Pubmed]
Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Adler, M., Davey, D.D., Phillips, G.B., Kim, S.H., Jancarik, J., Rumennik, G., Light, D.R., Whitlow, M. Biochemistry (2000) [Pubmed]
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. Phillips, G.B., Buckman, B.O., Davey, D.D., Eagen, K.A., Guilford, W.J., Hinchman, J., Ho, E., Koovakkat, S., Liang, A., Light, D.R., Mohan, R., Ng, H.P., Post, J.M., Shaw, K.J., Smith, D., Subramanyam, B., Sullivan, M.E., Trinh, L., Vergona, R., Walters, J., White, K., Whitlow, M., Wu, S., Xu, W., Morrissey, M.M. J. Med. Chem. (1998) [Pubmed]
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. Abendschein, D.R., Baum, P.K., Verhallen, P., Eisenberg, P.R., Sullivan, M.E., Light, D.R. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031). Post, J.M., Sullivan, M.E., Abendschein, D., Ewing, J., Hinchman, J.W., Light, D.R. Thromb. Res. (2002) [Pubmed]
Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. Abendschein, D.R., Baum, P.K., Martin, D.J., Vergona, R., Post, J., Rumennik, G., Sullivan, M.E., Eisenberg, P.R., Light, D.R. J. Cardiovasc. Pharmacol. (2000) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.